A Randomized, Double-blind, Parallel-group, Phase III Study of MRA-SC in Rheumatoid Arthritis Patients with Inadequate Response to Tocilizumab Subcutaneous Injection 162 mg every 2 weeks

Trial Profile

A Randomized, Double-blind, Parallel-group, Phase III Study of MRA-SC in Rheumatoid Arthritis Patients with Inadequate Response to Tocilizumab Subcutaneous Injection 162 mg every 2 weeks

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SHINOBI
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 26 Jun 2017 According to a Chugai Pharmaceutical media release, the company obtained an approval by the Ministry of Health, Labour and Welfare (MHLW) for the additional dosage and administration of Actemra Subcutaneous Injection, reducing the dose interval to one week in patients with rheumatoid arthritis who inadequately respond to the bi-weekly dosage.
    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 25 Aug 2016 According to a Chugai Pharmaceutical media release, the company filed an application with the Ministry of Health, Labour and Welfare (MHLW) for the approval of an additional dosage of Actemra (Tocilizumab) Subcutaneous injection in patients with rheumatoid arthritis who inadequately respond to the every other week dosing regimen.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top